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Abstract
Primate lentivirus nef is required for sustained virus replication in vivo and accelerated progression to AIDS. While exploring
the mechanism by which Nef increases the infectivity of cell-free virions, we investigated a functional link between Nef and
Env. Since we failed to detect an effect of Nef on the quantity of virion-associated Env, we searched for qualitative changes
by examining whether Nef alters HIV-1 sensitivity to agents that target distinct features of Env. Nef conferred as much as 50-
fold resistance to 2F5 and 4E10, two potent neutralizing monoclonal antibodies (nAbs) that target the membrane proximal
external region (MPER) of TMgp41. In contrast, Nef had no effect on HIV-1 neutralization by MPER-specific nAb Z13e1, by the
peptide inhibitor T20, nor by a panel of nAbs and other reagents targeting gp120. Resistance to neutralization by 2F5 and
4E10 was observed with Nef from a diverse range of HIV-1 and SIV isolates, as well as with HIV-1 virions bearing Env from
CCR5- and CXCR4-tropic viruses, clade B and C viruses, or primary isolates. Functional analysis of a panel of Nef mutants
revealed that this activity requires Nef myristoylation but that it is genetically separable from other Nef functions such as the
ability to enhance virus infectivity and to downregulate CD4. Glycosylated-Gag from MoMLV substituted for Nef in
conferring resistance to 2F5 and 4E10, indicating that this activity is conserved in a retrovirus that does not encode Nef.
Given the reported membrane-dependence of MPER-recognition by 2F5 and 4E10, in contrast to the membrane-
independence of Z13e1, the data here is consistent with a model in which Nef alters MPER recognition in the context of the
virion membrane. Indeed, Nef and Glycosylated-Gag decreased the efficiency of virion capture by 2F5 and 4E10, but not by
other nAbs. These studies demonstrate that Nef protects lentiviruses from one of the most broadly-acting classes of
neutralizing antibodies. This newly discovered activity for Nef has important implications for anti-HIV-1 immunity and AIDS
pathogenesis.
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Introduction
Nef is a multifunctional pathogenicity factor expressed by
primate lentiviruses. Disruption of nef is associated with defective
virus replication in vivo and delayed pathology [1–3]. At the
cellular level, Nef has well-documented activities that include the
ability to downregulate cell-surface molecules CD4 [4–6] and
MHC-I [7,8], and to modulate the threshold activation state of T-
cells and macrophages [9–12]. Nef alleles derived from most SIVs
also down-regulate the TCR/CD3 complex [13–15]. In addition,
SIV Nef was recently found to counteract the restriction factor
BST-2 [16,17].
Perhaps the least understood of the many Nef functions is its
requirement for the production of virion particles with maximal
infectivity [18,19]. The magnitude of this activity is greatest when
particles are generated from lymphoid cells [20], though it is not a
consequence of CD4 downregulation by Nef during virion
production [18,21–26]. Nef can be found in virions, but there is
no evidence that Nef encapsidation is required to promote HIV-1
virion infectivity [27,28]. Other virion modifications, then, must
account for the higher infectivity of virions produced in the
presence of Nef. Additionally, clues about Nef function might be
gleaned from future comparative studies with glycosylated-Gag
from gammaretroviruses; despite the absence of sequence
homology with Nef, this protein substitutes fully for Nef in
promoting virion infectivity [20].
Nef has a well documented ability to interact with adaptor
protein complexes and to alter vesicular transport and the
selection of vesicle cargo [29]. In addition, we have found that
Nef interacts with the cellular GTPase dynamin 2 and requires
PLoS Pathogens | www.plospathogens.org 1 December 2011 | Volume 7 | Issue 12 | e1002442intracellular vesicle formation which depend on both dynamin 2
and clathrin to increase viral infectivity. Incidentally, the
cytoplasmic tail of Env from HIV and other retroviruses contains
sorting motifs that interact with components of the intracellular
vesicle transport system [30–32], so it is reasonable to suppose that
Nef might influence the trafficking and incorporation of Env, as
has been reported [33]. Nonetheless, previous studies have failed
to detect an effect of Nef on the quantity of HIV-1 Env
incorporated into virions [20,34]. Therefore, in the present study
we considered the possibility that Nef confers a qualitative, rather
than a quantitative effect, on Env encapsidation. To probe for
these putative modifications to virion-associated Env, we took
advantage of neutralizing antibodies (nAbs) and other reagents
that target distinct features of the Env glycoprotein, postulating
that Nef-induced alterations would influence their binding to Env
and therefore their neutralizing potency.
Results
Nef decreases HIV-1 sensitivity to neutralization by the
MPER-specific nAbs 2F5 and 4E10, but not Z13e1
To explore potential links between HIV-1 Nef and Env, we
posited that, if Nef modifies the retroviral glycoprotein, this
putative modification might alter susceptibility to Env-specific
neutralizing agents. For this purpose, a panel of HIV-1 entry
inhibitors was collected, each of which probes different features of
Env. Reagents included dextran sulphate, which targets the V3
loop of SUgp120 [35], soluble CD4 and the monoclonal antibody
b12 [36], which interact with the CD4 binding site on gp120,
monoclonal antibodies 17B [37] and E51 [38], which recognize
CD4-induced epitopes on gp120, monoclonal antibody 2G12
[39], which recognizes a carbohydrate-dependent antigen on
gp120, a goat polyclonal antiserum raised against the entire gp120
protein, monoclonal antibodies 2F5, 4E10 and Z13e1 [40–42],
each of which target residues within the membrane proximal
extracellular region (MPER) of TMgp41, and the peptide T20
[43], which inhibits fusion via association with the 6-helix bundle.
The sensitivity of wild-type HIV-1NL4-3 to each of these reagents
was compared to that of Nef-defective HIV-1NL4-3. Pairs of these
otherwise isogenic viruses were collected from the supernatant of
acutely infected Jurkat T cells, normalized by exogenous reverse
transcriptase activity, and inoculated onto TZM-bl reporter cells
in the presence of the specified inhibitors. These cells bear a Tat-
responsive, b-galactosidase reporter, and infectious events were
enumerated by in situ X-gal staining of the target cell monolayer.
Under these conditions, Nef increased the infectivity of lab strain
HIV-1NL4-3 by up to 30-fold [20]. The Nef-positive virus inoculum
would therefore have to contain 30-fold less virus particles than the
Nef-defective counterpart in order to produce the same amount of
infected cells. This would result in a 30-fold increase of nAb/
antigen ratio for the wild-type virus compared to the Nef-defective
virus. To normalize the virus infectious titres, while maintaining a
similar antibody/antigen ratio between samples, viruses were first
equalized based on their RT-activity, which estimates the physical
amount of virions. The infectious titers were then normalized by
adding 15 mM of the reverse transcriptase inhibitor AZT to the
wild-type virus, a concentration that reduced virion infectivity 30-
fold (Figure S1A).
Nef had no detectable effect on the sensitivity of HIV-1NL4-3 to
any of the reagents targeting gp120 (Figure 1A). In contrast, wild-
type HIV-1NL4-3 was significantly less sensitive than its Nef-
defective counterpart to neutralization by 2F5 and 4E10, two of
the three monoclonal antibodies which target the MPER of
TMgp41 (Figure 1B and Figure S1B). IC50 values derived from the
fitted sigmoidal curves (Table S1) revealed that Nef increased the
concentrations of 2F5 and 4E10 required to neutralize HIV-1NL4-3
by 5 to 10 fold (Figure 1C). However, Nef did not affect HIV-1NL4-
3 sensitivity to Z13e1, a monoclonal antibody that also targets the
MPER, nor did it alter sensitivity to the fusion inhibitor T20.
The reproducibility of these results was tested under a variety of
experimental conditions. The specific effect of Nef on susceptibility
to neutralization by 2F5 was equally apparent by measuring Tat
transactivation of a luciferase reporter, rather than b-galactosi-
dase, in TZM-bl transduced cells (Figure S1C). Differential
sensitivity of the two viruses to 2F5 was observed when wild-type
and nef-defective HIV-1NL4-3 stocks were generated by transfection
of proviral DNA, rather than by infection, of Jurkat T cells (Figure
S1D). The effect was also reproduced with a different reporter cell
line (Ghost-X4-R5) in which infection activates a GFP reporter
(Figure S1E). Though the data shown with HIV-1NL4-3 in Figure 1
was obtained with infectivity normalized by AZT, the relative
effect of Nef on neutralization sensitivity was evident whether or
not infectivity was normalized with AZT (Figure S1F) and
remained significant when inocula were normalized according to
infectious titre, disregarding RT activity (Figure S1G).
The effect of Nef on neutralization by 2F5 and 4E10 is not
a consequence of an effect on Env incorporation
In the above experiments, virus stocks were produced in CD4
+
Jurkat T cells. Since Nef downregulates CD4 from the cell surface,
Env incorporation into virions in the absence of Nef might be
perturbed by interference from CD4 [44,45]: the requirement for
a higher concentration of antibody to neutralize wild-type virus
could result from greater quantity of Env incorporation into the
wild-type than into the Nef-negative virus. This explanation seems
unlikely since Nef caused decreased sensitivity to only two of the
eleven neutralizing agents that target Env tested here. Nonetheless,
to investigate this possibility directly, the effect of Nef on the
efficiency of Env incorporation into virions was analyzed. Virions
produced in Jurkat T cells by wild-type and Nef-negative HIV-1
were pelleted through a sucrose cushion and subjected to
immunoblotting with a polyclonal antibody against SUgp120. A
control sample expressing env in the absence of gag excluded that
the Env signal in the virion pellet was due to contamination from
Author Summary
Nef is a pathogenic factor expressed by primate lentivi-
ruses. HIV-1 virions produced by cells that express Nef
acquire unknown modifications that allow them to infect
new target cells with higher efficiency. We hypothesized
that Nef might alter the structure or function of the HIV-1
Env glycoproteins. In this study we tested whether Nef
alters the sensitivity of HIV-1 to several agents that inhibit
HIV-1 by binding to different parts of Env. We found that
Nef confers 10 to 50-fold resistance to neutralization by
two antibodies (2F5 and 4E10) that belong to one of the
most powerful classes of neutralizing agents, which are
active against a wide range of HIV-1 isolates. We
established that Nef decreases the recognition of the virus
particles by these antibodies, which bind to a domain of
the Env adjacent to the retroviral membrane (MPER). Env
from diverse HIV-1 isolates are equally sensitive to this
activity, and Nef proteins derived from both HIV-1 and SIV
retain the activity. By protecting lentiviruses from one of
the most broadly-acting classes of neutralizing antibodies,
this new activity of Nef might make a significant
contribution to AIDS pathogenesis.
Nef and MPER Neutralization
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gp41) were associated with wild-type and Nef-defective virions, as
visualized by Western blot (Figure 2A). For a more precise
quantification of the Env incorporated into particles, the same
virus samples were tested by an ELISA assay to quantify virion-
associated gp120 (Figure 2B), which revealed that a similar
amount of Env was present in virus samples, irrespective of nef.
The effect of Nef on neutralization, therefore, does not reflect
differential incorporation of Env into virus particles.
Nef decreases sensitivity to neutralization by 2F5 and4E10
of HIV-1 virions bearing Envs from diverse viral strains
Env glycoproteins encoded by laboratory-adapted strains such
as HIV-1NL4-3 are not representative of those viruses most
commonly found in natural infection. HIV-1NL4-3 uses CXCR4
as a co-receptor whereas the majority of HIV-1 strains in people
are CCR5-tropic [46]. Additionally, lab strains are generally more
sensitive to antibody-mediated neutralization of cell-free virions
than are primary isolates [47,48]. Therefore, the effect of Nef on
neutralization of HIV-1 bearing CCR5-tropic Envs from primary
isolates was examined. Wild-type and Nef-negative HIV-1
particles, pseudotyped with EnvJRFL, were produced by transfect-
ing Jurkat cells with env-defective HIV-1NL4-3 proviral DNA,
together with the EnvJRFL expression plasmid. Surprisingly, in
contrast to the experiments with EnvNL4-3, in the absence of nAb,
Nef caused no increase in the infectivity of virions pseudotyped
with EnvJRFL; particle normalization based on RT activity resulted
in equal infectivity for the wild-type and Nef-negative virion
stocks, obviating the need for AZT to normalize infectivity. As
Figure 1. Nef increases HIV-1NL4-3 resistance to 2F5 and 4E10 but not to other neutralizing agents targeting Env. Neutralization of
wild-type and Nef-defective HIV-1NL4-3 by the indicated neutralizing agents targeting gp120 (A) or gp41 (B). The residual infectivity is relative to that
of untreated viruses considered as 100%. C, Fold-change of IC50 values, derived from the fitted sigmoidal curves, caused by Nef. Neutralization was
performed three times independently. Shown are the mean values and SD.
doi:10.1371/journal.ppat.1002442.g001
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neutralization by 2F5 or 4E10, but not by 2G12, b12 or Z13e1,
was decreased by Nef (Figure 3A). The same specific effect of Nef
on sensitivity to nAb activity was observed with EnvSF162
(Figure 3B).
HIV-1NL4-3, HIV-1JRFL, and HIV-1SF162 are all clade B strains,
the subgroup most common in the USA and Europe. In other
regions of the world, non-clade B viruses predominate. In sub-
Saharan Africa, for example, where the prevalence of HIV-1 is
highest [49], clade C is common. Env glycoproteins from two
primary, clade C viruses [50] were therefore tested for effects of
Nef on sensitivity to nAbs. As previously reported [50], the clade C
Env glycoproteins were insensitive to neutralization by 2F5 (data
not shown). Virions pseudotyped with either of the two clade C
Envs were 10 to 50-fold less sensitive to neutralization by 4E10 in
the presence of Nef than in the absence of Nef (Figure 3C). Neither
clade C Env was neutralized by 2G12 (not shown). One of the two
was neutralized by b12, but Nef did not change the sensitivity of
HIV-1 to neutralization by this antibody. Overall, then, the
specific effect of Nef on the sensitivity to 2F5 and 4E10 was
observed with Env glycoproteins derived from different clades,
with either co-receptor preference, and irrespective of virus
adaptation to tissue culture.
The effect of Nef on neutralization by 2F5 and 4E10 is not
a consequence of the effect of Nef on virion infectivity
The effect of Nef on nAb activity was originally examined for
the purpose of identifying virion modifications that correlate with
the Nef-associated increase in virion infectivity. The different viral
pseudotypes used in this study had different levels of intrinsic
infectivity (Figure S2), and Nef had a highly variable effect on
infectivity. This was greatest (30-fold) when virions bore HIV-
1NL4-3 Env, intermediate (9-fold) for Env from HIV-1SF162,
minimal (2 to 4-fold) for the two clade C Envs, and undetectable
for EnvJRFL (Figure 4A). In contrast, the effect of Nef on sensitivity
to neutralization by 2F5 and 4E10 was the same for EnvJRFL as it
was for EnvNL4-3, and significantly greater than EnvNL4-3 for the
clade C Envs (Figure 4B). Thus, the effect of Nef on nAb sensitivity
does not correlate and therefore is not a consequence of the Nef-
mediated increase of infectivity. Since the infectivity of HIV-1
pseudotyped with the EnvJRFL was not changed by Nef, using
viruses bearing this envelope glycoprotein avoids the problem of
dealing with unequal infectious titres. JRFL Env was therefore
used for most of the subsequent experiments.
The effect of Nef on neutralization by 2F5 and 4E10 is not
a consequence of CD4 expression in producer cells
Nef downregulates CD4. Therefore, in the absence of Nef, the
higher levels of CD4 that result might interfere with the function of
Env. To test whether the effect of Nef on neutralization depended
on CD4 expression in producer cells, HIV-1NL4-3 was generated
from Jurkat D1.1, a CD4 negative subclone of Jurkat cells, and
from HSB-2 [51], another CD4-negative T cell line. In both cases,
the effect of Nef on MPER neutralization by 2F5 was similar in
magnitude to the effect observed with virions produced from CD4-
positive Jurkat (Figure 5A and Figure 1). To further investigate the
variability of this activity of Nef in different producer cell types,
HIV-1NL4-3 pseudotyped with the EnvJRFL was also produced
from a panel of different cell lines, including the T-cell lines MT4
and CEM-SS, the B-cell line DG75, and the adherent cells
HEK293T and TE671. Nef altered MPER neutralization of
viruses produced from all cell lines tested (Figures 5B and C).
However, virus produced from HEK293T was only minimally
responsive to this effect. Although small in magnitude, the effect of
Nef on the IC50 of both 2F5 and 4E10 was significant (p,0.05
calculated by 2-tail Mann-Whitney test) and specific, since Nef did
not alter susceptibility to neutralization by 2G12 (Figure S3).
These results show that the effect of Nef on neutralization does not
depend on CD4 expression in producer cells. Moreover, the
magnitude of this effect may depend on other cell-type-specific
factors.
Nef increases 2F5 and 4E10 neutralization resistance of
virus produced from primary cells
To test whether Nef alters the neutralization sensitivity of virus
generated by cells naturally infected by HIV, the effect was also
tested on viruses produced with PMBCs derived from three
different donors. Virus was generated by infecting PBMCs with a
modified version of NL4-3 where EnvJRFL replaces the NL4-3
sequence. Using all three donors, the Nef-defective viruses were at
least 10-fold more sensitive to neutralization by 2F5 and 4E10
than wild-type viruses, while their sensitivity to b12 remained the
same (Figure 6). Nef, therefore, affects the neutralization sensitivity
of virus derived from primary cells.
Figure 2. Nef does not alter the efficiency of Env incorporation
into virus particles. A. Western blotting of pelleted wild-type and
Nef-defective HIV-1NL4-3 virus particles and producer cells extracts
(Jurkat), showing abundance of gp120, gp41 and Gag. A sample
expressing an env-defective HIV-1NL4-3 (no Env) and a sample
expressing a gag-defective provirus construct (no Gag) were used to
control the assay specificity. B. Quantitative gp120 Elisa of the same
samples shown in A. Results show average and standard deviation of
triplicate determinations.
doi:10.1371/journal.ppat.1002442.g002
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4E10 is conserved among different Nef alleles
To determine if this new activity is conserved among Nef
proteins encoded by different lentiviruses, virions were produced
by transfecting Jurkat T cells with a nef-defective HIV-1HXB2
provirus, together with Nef expression plasmids from a lab-
adapted, clade B virus (HIV-1LAI), a primary, clade C virus, and
from SIVAGM. With virions bearing EnvHXB2, all three nef alleles
Figure 3. Virus particles pseudotyped with Env Glycoproteins derived from diverse HIV-1 isolates are responsive to the Nef effect
on the susceptibility to 2F5 and 4E10. Neutralization of Nef-positive and Nef-defective HIV-1NL4-3 virus particles pseudotyped with Env
glycoproteins derived from HIV-1JRFL (A), from HIV-1SF162 (B) and from two HIV-1 subgroup C isolates (C). Neutralization was performed three times
independently. Shown are the mean values and SD.
doi:10.1371/journal.ppat.1002442.g003
Figure 4. The effect of Nef on neutralization does not depend on the effect of Nef on infectivity. A, fold-increase of infectivity caused by
Nef on HIV-1NL4-3 pesudotyped with Env glycoproteins derived from the indicated HIV-1 isolates, measured on TZM-bl reporter cells. B, fold-increase
of 4E10 IC50 for the same viral pseudotypes, derived from the experiments shown in Figure 3, obtained by dividing the IC50 of the Nef-positive virus
with that of the Nef-defective virus.
doi:10.1371/journal.ppat.1002442.g004
Nef and MPER Neutralization
PLoS Pathogens | www.plospathogens.org 5 December 2011 | Volume 7 | Issue 12 | e1002442enhanced virion infectivity (Figure S4A) and conferred 5 to 10-fold
resistance to 2F5 (Figure 7A). When HIV-1NL4-3 particles were
pseudotyped with EnvJRFL, none of the nef alleles increased virion
infectivity (Figure S4B), but all decreased sensitivity to neutrali-
zation by 4E10, 5 to 15-fold (Figure 7B), mirroring the nAb result
obtained using EnvHXB2. This indicates that the effect of Nef on
neutralization is conserved among disparate nef alleles, and
confirms the independence of this phenotype from the effect on
virion infectivity.
Like Nef, Glycosylated-Gag from MLV increases HIV-1
resistance to 2F5 and 4E10
MoMLV Glycosylated-Gag (Glycogag) substitutes for Nef in
promoting HIV-1 infectivity but differs from Nef in that it does not
downregulate MHC-I or CD4 [20]. To determine if Glycogag
decreases susceptibility to neutralization by 2F5 or 4E10, EnvJRFL-
pseudotyped single-cycle Nef-positive and Nef-defective viruses
(Figure 8) were produced in Jurkat T cells by co-transfection of
provirus constructs with plasmids expressing MoMLV-Glycogag
or an empty control vector. Glycogag conferred to HIV-1 a
decrease in sensitivity to 2F5 and 4E10 of identical magnitude to
that produced by Nef. Glycogag expression did not further
decrease 2F5 and 4E10 sensitivity of wild-type HIV-1, indicating
that the activities of Nef and glycogag on susceptibility to
neutralization are redundant. The absolute infectivity of the
EnvJRFL pseudotypes was unaffected by either protein (Figure
S5A) confirming that the effect on neutralization is not linked to
enhanced infectivity. Glycogag had a similar effect on the
susceptibility to neutralization using HIV-1 bearing EnvNL4-3
(Figure S5B), which is also fully sensitive to the effects of Nef and
Glycogag on infectivity (Figure S5C). Altogether, results show that
the activity of Nef on neutralization is not a prerogative of the
lentivirus protein.
The effect on susceptibility to neutralization by 2F5 and
4E10 is genetically separable from other activities of Nef
Nef is a pleiotropic factor able to perform many activities and,
via distinct surfaces, to interact with a plethora of cellular proteins.
Figure 5. The effect of Nef on neutralization does not depend on the presence of CD4 in producer cells and is observed with HIV-1
derived from various cell lines. A, neutralization of wild-type and Nef-defective HIV-1NL4-3 produced in two CD4-negative T lymphoid cell lines. B,
Neutralizationofwildtype andNef-defectiveNL4-3pseudotypedwithEnvJRFL producedintheindicatedcelllines.C,Fold-changeofIC50 valuesfor4E10
and 2F5, derived from the fitted sigmoidal curves shown in B, caused by Nef. Neutralization was performed three times independently. Shown are the
meanvaluesandSD.ThesignificanceofthedifferencesofIC50valueswereassessedby2-tailMann-Whitneytest,whichretrievedforallsamplesp,0.05.
doi:10.1371/journal.ppat.1002442.g005
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other activities, a panel of Nef mutants (Table 1) was screened for
effects on antibody neutralization. We tested the Nef mutated on
the SH3 binding domain (PP72,75AA) [52], the mutant unable to
interact with adaptor protein complexes, (LL164,165AA) [53–55],
mutants unable to interact with dynamin 2 and thioesterase
(L112A and FD121,123AA) [56], Nef mutated on the putative
cholesterol binding motif (LYYK/RSSL) [57], and finally the
myristoylation defective Nef (GG2,3AA) [27]. All nef mutations
were inserted into an env-defective HIV-1NL4-3 provirus to allow
expression in cis together with the rest of the viral genome. Single
cycle of replication virus was generated by transfecting Jurkat cells
with the virus constructs and the EnvJRFL expression plasmid, and
the effect of Nef on sensitivity of neutralization by 2F5 and 4E10
tested using TZM-bl reporter cells.
Among all Nef variants, only the myristoylation mutant had a
defective activity on neutralization sensitivity (Figure 9 and Figure
S6). In contrast, all other mutants retained the ability to decrease
virus sensitivity to both 2F5 and 4E10. Since mutations abrogating
Nef capabilities to enhance infectivity, to recruit src kinases, and to
Figure 6. Nef alters the neutralization sensitivity of virus derived from primary cells. Neutralization of wild-type and Nef-defective HIV-
1NL4-3 pseudotyped with JRFL Env produced in PBMC from three different donors, with the indicated nAbs. Neutralization was performed three times
independently. Shown are the mean values and SD.
doi:10.1371/journal.ppat.1002442.g006
Figure 7. The effect of Nef on neutralization is conserved among different Nef alleles. Neutralizion of HIV-1 HXB2 by 2F5 (A) and
neutralization of HIV-1NL4-3 pseudotyped with EnvJRFL neutralized by 4E10 (B). IC50 derived from the sigmoidal curves are shown on the right. As
indicated, nef alleles were expressed in trans in producer cells. Neutralization was performed three times independently. Shown are the mean values
and SD.
doi:10.1371/journal.ppat.1002442.g007
Nef and MPER Neutralization
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neutralization, we conclude that the latter is genetically distin-
guishable from the others and that the effect of Nef on
neutralization is a novel activity. Being Nef myristoylation
important to mediate the correct interaction of the protein with
the lipid environment, results suggest that its association with the
cell membrane is crucial for the activity on neutralization.
The cytoplasmic tail of TMgp41 is dispensable for the
effect of Nef on neutralization
HIV-1 TMgp41 interacts with intracellular transport machinery
via leucine- and tyrosine-based sorting signals in the 151 aa
cytoplasmic tail [30–32]. To determine if the ability of Env to
engage the vesicular transport machinery is required for the effect
of Nef on neutralization sensitivity, a stop codon was engineered
that allows translation of HIV-1JRFL TMgp41 up to the 7
th aa of
the cytoplasmic tail. As previously reported [58], absence of the
cytoplasmic tail had little effect on virion infectivity which, like full-
length EnvJRFL (Figure 3D), remained insensitive to Nef (not
shown). Despite the lack of the cytoplasmic tail, Nef conferred 12-
fold resistance to neutralization by 4E10, but not by 2G12
(Figure 10). The cytoplasmic tail of TMgp41 is therefore not
required for the activity of Nef on neutralization. Given that Nef is
a cytoplasmic protein, and that the cytoplasmic tail of TMgp41 is
the only part of Env within the cytoplasm, this result indicates that
the effect of Nef on neutralization does not involve direct contact
between Nef and Env.
Nef decreases the binding of 2F5 and 4E10 to HIV-1
virions
A quantitative, virion immunoprecipitation assay was estab-
lished to determine if Nef decreases the efficiency by which 2F5
and 4E10 bind HIV-1 virions. Protein G-coupled beads decorated
with the nAb to be tested were incubated with suspensions of
EnvJRFL–pseudotyped, Nef-positive and Nef-defective viruses that
had been normalized by RT activity prior to incubation. Beads
were washed to remove unbound virions and the amount of virus
captured was quantified using a PCR-based, reverse transcriptase
assay [59]. Preliminary experiments showed that magnetic beads,
rather than porous sepharose beads, provide a much superior tool,
because non-specific binding of virus particles (either in the
absence of antibody or Env) is negligible (Figure 11). In contrast,
the background produced by sepharose beads was 10 to 100-fold
higher than that obtained with magnetic beads, critically reducing
the sensitivity of the assay (data not shown).
The efficiency of virion capture varied among nAbs (Figure 11).
However, in all cases, the amount of virus captured was
significantly higher than the background obtained with virions
devoid of Env or in the absence of nAb. 2G12, b12, and Z13e1
captured a similar amount of Nef-positive and Nef-defective
virions (Figure 11A). In contrast, up to four-fold more Nef-
defective than Nef-positive virus was captured by 2F5 and 4E10
(Figure 11B).
Since MoMLV Glycogag also decreased HIV-1 susceptibility to
the nAbs (Figure 8), the effect of Glycogag on virion binding by
2F5 and 4E10 was also tested. The capture assay was repeated
Figure 8. MoMLV Glycogag, like Nef, increases HIV-1 resistance to 2F5 and 4E10. Comparison of the activity of Nef and MLV Glycogag on
HIV-1 neutralization by MPER targeting nAbs (A) and IC50 values (B). Nef-positive and Nef-defective HIV-1NL4-3 pseudotyped with EnvJRFL were
neutralized by 2F5 and 4E10. As indicated, Glycosylated Gag or an empty vector control were expressed in trans in producer cells. Neutralization was
performed three times independently. Shown are the mean values and SD.
doi:10.1371/journal.ppat.1002442.g008
Table 1. Properties of the Nef mutants analyzed in this study.
Mutation Disrupt interaction with: Defective function ref
GG2,3AA N-myristoyl transferase CD4 downregulation (partial) MHC-I downregulation
Infectivity enhancement
(27)
PP72-75AA SH3 kinases T-cell activation (52)
L112A Dynamin 2 Infectivity enhancement (20)
FD121,123AA Dnamin2, thioesterase CD4 and MHC-I downregulation Infectivity enhancement (20, 56)
LL164-165AA Adaptor protein complexes CD4 downregulation Infectivity enhancement (53-55)
LYYK/RSSL Cholesterol Infectivity enhancement (57)
doi:10.1371/journal.ppat.1002442.t001
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presence or absence of Glycogag. Glycogag specifically decreased
the efficiency of Nef-defective virion capture by 2F5 and 4E10
(Figure 11C). It did not change the efficiency of capture of the Nef-
positive virus, indicating that the activity of the two proteins was
redundant. These results mirror the effect of Nef and Glycogag on
sensitivity to neutralization by these antibodies, and provide direct
evidence that these proteins specifically reduce the efficiency of
HIV-1 virion binding to 2F5 and 4E10.
Discussion
Here we describe a novel function for lentiviral Nef: it renders
the HIV-1 virion refractory to the broadly-neutralizing antibodies
2F5 and 4E10. This effect was extraordinarily specific, and not the
result of a global decrease in neutralization sensitivity, since Nef
had no effect on sensitivity to nine other, well-characterized Env
neutralizing agents. This Nef activity targets a property that is
conserved among diverse HIV-1 Envs, irrespective of clade,
chemokine receptor preference, or adaptation to tissue culture.
Divergent HIV-1 Nef proteins, as well as an SIVAGM Nef that
shares ,40% amino acid identity with HIV-1 Nef, all have this
activity, suggesting that it reflects a core Nef function. Analyses of
Nef mutants revealed that the activity on neutralization suscep-
tibility is a novel and yet unreported activity, mechanistically
distinct from other Nef activities.
This same specific effect on HIV-1 sensitivity to neutralization
by 2F5 and 4E10 was evident with MoMLV Glycogag, indicating
that this activity is shared by an unrelated protein encoded by a
gammaretrovirus. The TM glycoprotein of gammaretroviruses
contains an MPER with clusters of aromatic residues like those in
the HIV-1 MPER [60]. Additionally, there are reports that the
gammaretrovirus MPER is targeted by potent neutralizing
antibodies [60–62]. Taken together, these findings suggest that,
like lentiviruses, gammaretroviruses encode a protein to protect
from similar broadly-acting nAbs that target the MPER of TM.
Though HIV-1 particles pseudotyped with Env glycoproteins
from a range of disparate HIV-1 isolates were all equally sensitive
to the effect of Nef on neutralization sensitivity, the same virion
pseudotypes responded very differently from one another with
respect to the enhancing effect of Nef on virion infectivity. In
particular, virions bearing EnvJRFL were fully sensitive to the Nef
effect on neutralization but totally unresponsive to the Nef effect
on infectivity. Such large Env-dependent variation in the effect of
Nef on infectivity has not previously been reported. Given the
evidence that virions pseudotyped with virus glycoproteins driving
entry to an endocytic compartment are not sensitive to the effect of
Nef on infectivity [63], we hypothesize that different HIV-1 Envs
could target cell entry of virus particles to different pathways,
altering the requirement of Nef for optimal infectivity. Decipher-
ing the primary sequence determinants for Env responsiveness
may prove valuable for a better understanding of the mechanism
by which Nef promotes virion infectivity. Though the neutraliza-
tion experiments reported here were initiated to understand how
Nef promotes virion infectivity, the lack of correlation indicates
that the two phenotypes are independent. This conclusion is also
Figure 9. Nef myristoylation is required for its activity on neutralization. IC50 of 2F5 and 4E10 for HIV-1NL4-3 pseudotyped with EnvJRFL and
carrying the indicated Nef mutations. Values were derived from the sigmoidal curves shown in Figure S6. Neutralization was performed three times
independently. Shown are the mean values and SD.
doi:10.1371/journal.ppat.1002442.g009
Figure 10. The effect of Nef on neutralization does not depend on the cytoplasmic tail of HIV-1 Env. Neutralization of wild type and Nef-
defective HIV-1NL4-3 virus particles pseudotyped with EnvJRFL mutants lacking the cytoplasmic tail, by 2G12 and 4E10 (A). Fold-increase of IC50 caused
by Nef (B). Neutralization was performed three times independently. Shown are the mean values and SD.
doi:10.1371/journal.ppat.1002442.g010
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activity on virus infectivity, retain an unaltered ability to decrease
sensitivity to neutralization.
A screen of Nef mutants revealed that Nef myristoylation is
required for the activity on neutralization, while mutations
impairing the interaction of Nef with some well characterized
cellular partners, such as src kinases, adaptor proteins and
dynamin 2, had no fundamental effect on this activity. Accord-
ingly, overexpression of dominant-negative dynamin 2 had no
effect on the ability of Nef to increase HIV resistance to 2F5 and
4E10 (Figure S7). We therefore conclude that the effect on
neutralization susceptibility is unrelated to other Nef activities.
Deletion of the TMgp41 cytoplasmic tail, and the intracellular
trafficking signals that it possesses [30–32], did not alter the effect
of Nef on neutralization sensitivity. This activity, then, is unlikely
to involve intracellular redistribution of Env resulting from direct
interaction with Nef, or from indirect effects of Nef on cellular
signaling components. Additionally, the activity cannot be
ascribed to an effect of Nef on Env encapsidation since the level
of virion-associated Env was unchanged by Nef. The effect of Nef
remained the same in the absence of CD4 expression in producer
cells excluding more subtle interference of Env by its cognate
receptor.
In response to sequential binding of gp120 to CD4 and
chemokine receptors, gp41 undergoes a series of structural
changes, first an extended conformation, followed by a fusogenic
bundle of six a-helices called the trimer of hairpins. Previous
reports proposed that 2F5 and 4E10 bind to the pre-hairpin
intermediate with an extended conformation [64]. However, Nef
had no effect on sensitivity to T20 (Figure 1A), a fusion inhibitor
that binds to the prehairpin intermediate [43], or to fusion of cell-
free virions with cells [26,65]. Perhaps the most compelling
evidence that the extended conformation is not necessary for
binding by 2F5 and 4E10 is the experiment presented here
showing that these antibodies capture virus particles in the absence
of receptor engagement (Figure 11). These findings are in
agreement with recent studies showing that the extent of 2F5
and 4E10 binding to cell-free virions correlates with neutralization
[66], and causes gp120 shedding [67]. Thus, the data here
demonstrate that Nef attenuates the interaction of MPER-specific
nAbs with cell-free virions, rather than modulating structural
changes that occur subsequent to encounter with cells.
Based on recent structural studies, the MPER epitopes targeted
by 2F5 and 4E10 are believed to be partially embedded within the
lipid bilayer of the virion [68–70]. The neutralizing activity of
these antibodies is proposed to rely on their ability to interact with
membranes [71–73], and is dependent on the long hydrophobic
CDR3 loop [74,75]. This might facilitate their interaction with the
lipid bilayer and be instrumental for the ability to dock with the
epitope, to extract hydrophobic residues from the lipid environ-
ment [64,70] and ultimately contribute to the neutralizing activity
[73,76]. In contrast, neutralization with Z13e1 might not require
an interaction with lipids [64], in line with evidence that the
crucial residues of the epitope are located on the solvent exposed
face of MPER [64]. Interestingly, several studies have reported a
link between Nef and lipid biosynthesis and trafficking. Nef was
reported to induce expression of genes involved in cholesterol
biosynthesis [77], to reduce cholesterol efflux [78] , to enhance the
raft-like character of virions via an increase in their cholesterol
content [57] and/or a preferential incorporation of sphingomyelin
Figure 11. Nef and MoMLV Glycogag specifically alter the capture efficiency of HIV-1 by 2F5 and 4E10. EnvJRFL virus pseudotypes (Env+)
captured by magnetic beads conjugated with the indicated antibodies, targeting gp120 (A) or gp41 (B), in the presence or absence of Nef, quantified
by RT activity and expressed as mU of HIV-1 RT. C, direct comparison of the abilities of Nef and Glycogag to alter virus capture by 2F5, 4E10 and 2G12.
The specificity of the virus capture was assessed by measuring capture of Env-defective virus particles (Env-) by magnetic beads conjugated with
each antibody, or capture of EnvJRFL pseudotypes by non-conjugated magnetic beads (noAb). Data show average values and standard deviation from
triplicate independent captures.
doi:10.1371/journal.ppat.1002442.g011
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the interaction of 2F5 is favored by phospholipids with negatively
charged head groups [80], and the association of the MPER with
membranes is favored by the presence of sphingomyelin and
cholesterol [81]. We therefore propose that Nef, by altering the
lipid composition of the virion, alters the susceptibility to
neutralization by 2F5 and 4E10, either by reducing the
preliminary contact of the antibodies with the virus particle,
and/or by increasing the strength of the association of the MPER
with the viral membrane (Figure 12), which would make the
epitopes less accessible to the antibodies. Supporting this
hypothesis, our experiments revealed that the effect on neutral-
ization is totally dependent on Nef myristoylation, which is
essential for the localization of Nef into lipid rafts [82–84] and was
found to be required for enhanced synthesis and efflux of
cholesterol. We found that mutating the cholesterol binding motif,
which had been initially linked to an increased cholesterol content
of virus particles, does not abrogate the activity on neutralization.
However, the role of such a binding motif, however remains
unclear, in light of a more recent study [79] which failed to
confirm its cholesterol binding function.
We have observed variability of the magnitude of the Nef
activity on neutralization when screening virus produced by
different cell lines, observing that virus generated by HEK293T
cells is only minimally responsive. Interestingly, it has been
recently reported that the lipid composition of cellular membranes
and viruses derived from different cell lines can vary significantly.
The composition of the cell membrane isolated from HEK293T
and from the T-cell line MT4, as well as the lipid pool of progeny
viruses derived from these cell lines were found to vary
significantly in their sphingomyelin content [85]. It is therefore
plausible that cell-type specific variabilities of the membrane lipid
composition modulate the responsiveness of the progeny virus to
the effect of Nef on neutralization.
The most potent monoclonal antibodies targeting Env have
been cloned from bone marrow and B-cells of HIV-1 infected
patients, and were instrumental in identifying crucial antibody
specificities associated with protection. Within gp120, these
antibodies were found to target the CD4 binding site (e.g. b12
and VRC01 [36,86]), CD4 inducible epitopes (e.g. 17B [37] and
E51 [38]), a carbohydrate dependent epitope (2G12 [39]) and a
quaternary structure-dependent epitope comprising the V2 and
V3 loops (e.g. PG16) [87]. Within gp41, antibodies targeting the
membrane proximal external region (MPER) were found to be the
most potent and broadly neutralizing, including the monoclonal
antibodies 2F5 and 4E10 [40,41] and Z13e1 [42]. The use of
MPER as an antigen to induce a protective immune response in
vivo has therefore been widely tested [88,89]. However, MPER-
specific neutralizing antibodies are only rarely found in HIV-1
infected subjects [90,91] and different immunization strategies
using the MPER have failed to induce significant neutralizing
immunity [88]. This could be the result of limited accessibility of
nAbs to such native epitopes which are located at the interface
with the retroviral membrane. By favoring the interaction of
MPER with the membrane Nef might contribute to hiding these
crucial viral epitopes from the humoral immune response. Long-
term nonprogression to AIDS has been reported in people infected
with Nef-defective HIV-1 [1–3]. It would be of interest to
determine if the strong, broadly neutralizing antibody responses
observed in some of these individuals [92] are caused by MPER
targeting antibodies.
Materials and Methods
Plasmids
Wild type, env-defective and nef-defective HIV-1NL4-3 and HIV-
1HXB2 provirus constructs have been previously described [34,93].
Nef mutations GG2,3AA, PP72,75AA, L112A, FD121,123AA,
LL164,165AA and LYYK202,206-208RSSL were introduced into
env-defective HIV-1NL4-3 by site directed mutagenesis. HIV-1
pseudotypes were produced using pSV-JRFL Env, pCAGGS
SF162 gp160, and the two subtype C env-encoding plasmids
SVPC13-ZM109F-PB4, SVPC16-CAP45.2.00.G3 (all from NIH
AIDS Research and Reference Reagent Program). Deletion of the
Env cytoplasmic tail was achieved by introducing a stop codon by
site directed mutagenesis in position 704 of the Env ORF in pSV-
JRFL env. The nef ORF of HIV-1 LAI (subtype B), 97ZA012
(subtype C) and SIVagm were expressed in PBJ5 plasmid as already
described [20]. Minimal active MoMLV glycogag, truncated at
residue 189, was also expressed in PBJ5, as already described [20].
Cell lines
Human lymphoblastoid Jurkat D1.1 (ATCC), HSB-2 (NIH
AIDS Research and Reference Reagent Program), Jurkat T
(modified to express the large T antigen from SV40), MT4, DG75
HAD and CEM-SS cells, were grown in RPMI (Invitrogen).
Human HEK 293T and TE671 cells, TZM-bl and GHOST
indicator cells (NIH AIDS Research and Reference Reagent
Figure 12. Model depicting the possible mechanism by which Nef specifically alters the accessibility of 2F5 and 4E10 MPER
epitopes to nAbs. Schematic conformation of the MPER in relation to the viral membrane in the absence (A) or presence (B) of Nef. Nef, by altering
the virion lipid composition, increases the strength of the association of the MPER with the viral membrane, decreasing specifically the accessibility of
the epitopes for 2F5 and 4E10, but not Z13e1, which is located on the exposed side of the MPER.
doi:10.1371/journal.ppat.1002442.g012
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supplemented with 10% fetal calf serum (PAA Laboratories) and
cell cultures were maintained at 37uC and 5% CO2.
Chemicals and antibodies
Soluble CD4, AZT, saquinavir, the monoclonal antibodies b12,
17B, 2G12, the goat polyclonal serum ARP401 and 4E10 were
obtained from the National Institute for Biological Standards and
Control (NIBSC). The peptide T20, and the antibodies E51, 2F5,
and Z13e1 were obtained from the NIH AIDS Research and
Reference Reagent Program. Dextran sulphate (MW 500,000) was
purchased from USB.
Virus production
Virions capable of a single round of replication were produced
by transfecting suspension-growing cells using electroporation and
adherent cells using calcium phosphate and Fugene 6 (Roche),
with env-deficient HIV-1 proviral DNA and vectors encoding
retroviral env glycoproteins at a 4:1 ratio. Virus pseudotypes were
harvested 48h after transfection. Replication-competent HIV-1
was harvested 48 hours after having infected Jurkat T cells or PHA
and IL-2 stimulated PBMC with VSV-G pseudotyped viruses.
Virus-containing supernatants were clarified by low speed
centrifugation, and filtered through 0.45 mm pore filters. Single
cycle infectivities were determined in triplicate by challenging
target cells with serially diluted viruses normalized based on their
reverse transcriptase activity [59,93]. HIV-1 infectivities were
revealed by staining infected TZM-bl cells with X-Gal as
described [20]. When replication-competent HIV-1 was used, to
limit replication to a single cycle and prevent syncytia formation,
saquinavir (1 mM) and dextran sulphate (20 mg/ml) were added 2
hour after infection.
Reverse transcriptase assay (SGPERT)
Reverse transcriptase (RT) activity in the supernatants was
quantified using a Sybr green I-based real-time PCR enhanced
RT assay (SGPER) that possesses both high sensitivity and an
extraordinary dynamic range. The assay is a modified version of
that described earlier [59]. Briefly, virions in cell-free supernatants
were disrupted by adding an equal volume of SGPERT lysis buffer
containing 0.25% Triton X-100, 50 mM KCl, 100 mM TrisHCl
pH7.4, 0.4 U/ml RNase inhibitor (RiboLock, MBI Fermentas).
Lysed virions were used for reverse transcription of MS2 RNA
template (Roche) [94]. Quantification of reverse transcribed
products was carried out in a CFX96 thermal cycler (Biorad)
using Sybr-Green I, hotstart Taq and reaction buffer (Fermentas),
and a MS2 primer set already described [94]. A standard curve
was obtained using known concentrations (expressed in functional
units) of recombinant HIV-1 RT (Ambion).
Neutralization assays
Sensitivities of the functional env-pseudovirus or replication
competent NL4-3 to neutralizing agents were assayed on TZM-bl
or GHOST cells, seeded onto 96-well tissue culture plates a day
prior to neutralization. Viruses were normalized based on RT
activity and the inocula were adjusted to produce between 1% and
3% infection of the monolayer. To equalize the level of infectivity
and obtain a similar amount of Nef-positive and Nef-negative
viruses, AZT was added to the Nef-positive virus at the final
concentration of 15 mM when replication competent HIV-1NL4-3
was used. Viruses were incubated with serially diluted neutralizing
agents for 1 hour at room temperature. The complexes were
added to indicator cells, incubated at 37uC for 2 hours, followed
by two washes with PBS before being cultured in fresh complete
DMEM. The cells were incubated at 37uC for a further 40 to 42
hours before staining for b-gal or prior to measurement of
luciferase (TZM-bl) or before flow cytometry (GHOST). When
replication-competent virus was used, protease inhibitor Saquin-
avir (1 mM) (NIBSC) and dextran sulphate (20 mM) (USB) was
added after the 2 PBS washes to limit replication to a single cycle
of infection and to prevent formation of syncytia.
Neutralization was measured by calculating the residual
infectivity of treated virus samples considering the infectivity of
the untreated sample as 100%. Fitted sigmoidal curves and IC50
were obtained using Prism (Graphpad) with the least square
variable slope method and using the dose-normalized response
protocol. Neutralizations were performed independently three
times with each combination of virus and antibody to be analyzed
and data shown are the average with standard deviations.
Statistical significance for all data sets was assessed by subjecting
the derived IC50 values from the triplicate independent
neutralizations to 2-tail Mann-Whitney test. Differences with
p,0.05 were considered significant. All differences in neutraliza-
tion sensitivity described in results were found to be significant
based on this test.
Western blot and ELISA analysis
To examine the association of Env with HIV-1 particles, viral
particles present in filtered culture supernatants were pelleted
through sucrose cushions as described [95]. Pelletable material
and cell lysates were analyzed by SDS-polyacrylamide gel
electrophoresis (PAGE) and Western blotting, using a mouse
monoclonal antibody to HIV-1 p55/p24, a rabbit antiserum to
GP120 (both from NIBSC, Centre for AIDS Reagents) and the
monoclonal anti-gp41 Chessie 8 (from NIH AIDS Research and
Reference Reagent Program).
Virus samples were also analyzed by ELISA. Briefly, lysates
were serially diluted in carbonate buffer (pH 9.4) and coated
overnight onto maxisorb 96 well plates (Nunc), blocked for 1 hour
with 2.5% non fat dry milk, and probed with a guinea pig anti-
gp120 serum (1:40 for 1.5 hours) followed by a HRP-conjugated
secondary antibody (Jackson, 1:10,000 for 1.5 hours). The signal
was developed with TMB substrate before being stopped with 2M
H2SO4 and measured at 450nm. A standard curve was generated
using serially diluted recombinant SF162 gp140.
Virus capture assay
An immunoprecipitation assay was used to study virus capture
by nAbs. 10 ml protein G magnetic beads (Dynabeads, Invitrogen)
were resuspended in 500 ml DMEM containing 10% FCS. For
each sample subjected to immunoprecipitation, 1 mg nAb and
10 ml of beads were incubated in complete medium at room
temperature with rocking to allow maximum nAb binding to
Protein G. The beads were then washed twice with complete
medium. Virus supernatant (500 ml) was added to the beads and
incubated for 1 hour 37uC, with rocking. Unbound viruses were
removed by 3 washes in complete medium. The virus bound to
magnetic beads was lysed with 10 ml SGPERT lysis buffer and
incubated for 10 minutes before being diluted 10-fold with
SGPERT dilution buffer. The diluted lysate was then centrifuged
at 800g for 1 minute to sediment the beads and the pelleted beads
immobilized on the tube by applying a magnet. 10 ml of the lysate
supernatant was then removed and used in the SG-PERT assay to
quantify the amounts of virus captured.
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Supporting Information
Figure S1 Nef increases HIV-1 resistance to 2F5 and
4E10. A, dose-response titration of AZT treatment of HIV-1NL4-3
WT, used to normalize the infectivity of the WT virus to that of
the Nef-defective mutant. HIV-1NL4-3 WT was treated with the
indicated concentrations of AZT and added to target cells for 2
hours. The residual infectivity is relative to that of the untreated
virus considered as 100%. B, TZM-bl monolayer infected with wt
and nef-defective HIV-1NL4-3 neutralized by the indicated amount
of antibody 2F5 and stained 48 hours after infection with X-gal.
Both viruses were first normalized based on RT-activity and then
wt HIV-1NL4-3 was treated with 15 mM AZT to equalize its
infectivity to the level of the Nef-negative HIV-1NL4-3.C ,
Neutralization of wild type and Nef-defective HIV-1NL4-3 by
2G12 and 2F5, after quantifying luciferase activity of the infected
TZM-bl target cells. D, neutralization of wild type and Nef-
defective HIV-1NL4-3 produced by transfection, rather than
infection, of Jurkat T cells, using nAb 2F5. E, Neutralization of
wild type and Nef-defective HIV-1NL4-3 by 4E10 inoculated onto
GHOST-CXCR4-CCR5 indicator cells and flow cytometry
analyses. F and G, Neutralization of wild type and Nef-defective
HIV-1NL4-3 by 2F5, using virus inocula normalized by RT activity,
without AZT treatment (F) or normalized based on infectious units
only and not by RT-activity (G). Residual infectivity is relative to
that of untreated viruses considered as 100%. Neutralization was
performed three times independently. Shown are the mean values
and SD.
(PDF)
Figure S2 Variability of the infectivity of HIV-1NL4-3
pseudotyped with Env glycoproteins derived from
different isolates. Viruses (the same used in Figure 3) were
produced by transfecting Jurkat cells with Nef-positive and Nef-
negative Env-defective provirus constructs and with plasmids
expressing the Env glycoproteins derived from the specified HIV-1
isolates. Viruses were titrated in triplicate on TZM-bl cells and
infectivity expressed in function of the RT-activity of the inocula.
(PDF)
Figure S3 Nef does not alter 2G12 neutralization
sensitivity of HIV-1 derived from HEK293T. Neutraliza-
tion sensitivity of Nef-positive and Nef-defective HIV-1NL4-3
produced in HEK293T pseudotyped with EnvJRFL and assesed
on TZM-bl indicator cells. The same virus samples were
neutralized with 2F5 and 4E10 and shown in Figure 5B.
Neutralization was performed three times independently. Shown
are the mean values and SD.
(PDF)
Figure S4 Effect of different nef alleles on HIV-1
infectivity. Infectivity of HIV-1HXB2 (A) and HIV-1NL4-3
pseudotyped with EnvJRFL (B) produced in Jurkat cells expressing
different nef alleles or an empty plasmid control. These viruses are
the same used in Figure 7. Infectivity was measured on TZM-bl
reporter cells in triplicate. Shown are the mean values and SD.
(PDF)
Figure S5 Glycogag alters HIV-1 sensitivity to 2F5 and
4E10. A, effect of MoMLV Glycogag on the infectivity HIV-1NL4-3
pseudotyped withthe envelopeglycoproteinfromHIV-1JRFLused
in Figure 8. B MoMLV Glycogag increases also 2F5 neutralization
resistance of HIV-1HXB2. Viruses were produced by co-transfection
of Jurkat cells with a Nef-defective HIV-1HXB2 provirus construct
along with a plasmid expressing Nef from HIV-1LAI, MoMLV
Glycogag or an empty vector control. The effect of HIV-1 LAI Nef
and MoMLV Glycogag on HIV-1HXB2 infectivity is shown in C.
Neutralization was performed three times independently. Shown
are the mean values and SD.
(PDF)
Figure S6 Activity of different Nef mutants on 2F5 and
4E10 neutralization sensitivity of HIV-1. HIV-1NL4-3
pseudotyped with the EnvJRFL and carrying the indicated
mutations in Nef were produced in Jurkat cells and assayed onto
TZM-bl indicator cells. Sigmoidal curves shown here were used to
derive the IC50 values reported in Figure 9. Neutralization was
performed three times independently. Shown are the mean values
and SD.
(PDF)
Figure S7 The activity of Nef on HIV-1 sensitivity to
neutralization does not depend on dynamin 2. Neutrali-
zation sensitivity of Nef-positive and Nef-defective NL4-3
pseudotyped with JRFL Env. Viruses were produced by co-
transfecting Jurkat cells with the provirus constructs, the Env
plasmid and a vector expressing Dynamin2 K44A or an empty
vector control. Neutralization sensitivity was tested as indicated.
Neutralization was performed three times independently. Shown
are the mean values and SD.
(PDF)
Table S1 IC50 values of the neutralization reagents
tested on wild type and Nef-defective HIV-1NL4-3, derived
from the fitted sigmoidal curves shown in Figure 1.
(PDF)
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